KRAS and colorectal carcinoma: Amplification in the human epidermal growth factor receptor 2 (HER2) gene (ERB2) has been described in approximately 3–4% of CRC patients, and is highly enriched in KRAS wild-type (6–8%) and MSI-H patients [14,15].